NCT05799963View on ClinicalTrials.gov

ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD

NAActive, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

March 31, 2026

Conditions
Coronary Artery Disease
Interventions
DEVICE

BioMatrix Alpha

Patient will be treated with BioMatrix Alpha

Trial Locations (9)

21244

Krankenhaus Buchholz, Buchholz

32758

Klinikum Lippe GmbH, Detmold

33604

Klinikum Bielefeld, Bielefeld

Unknown

University Hospitals Birmingham (UHB), Birmingham

United Lincolnshire Hospitals (ULH), Lincoln

The Grange University Hospital, Newport, Newport

BB2 3HH

Royal Blackburn Hospital, Blackburn

HU3 2JZ

Hull University Teaching Hospitals (HUTH), Hull

WN1 2NN

Royal Albert Edward Infirmary, Wigan

All Listed Sponsors
lead

Biosensors Europe SA

INDUSTRY

NCT05799963 - ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD | Biotech Hunter | Biotech Hunter